Related Experiment Videos
Gene therapy of hematologic malignancies.
1Department of Medicine, University of California San Diego, La Jolla 92093-0663, USA.
Seminars in Oncology
|October 26, 2000
Summary
Gene therapy is revolutionizing hematologic malignancy treatment by modifying cells to improve chemotherapy sensitivity and immune responses. This approach shows promise for effective future cancer therapies.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Hematologic malignancies present complex treatment challenges.
- Gene therapy offers novel strategies for combating these cancers.
- Current research focuses on enhancing treatment efficacy and safety.
Purpose of the Study:
- To explore the multifaceted applications of gene therapy in treating hematologic malignancies.
- To review methods for modifying hematopoietic stem cells, T cells, and neoplastic cells.
- To highlight recent advancements and clinical trial outcomes.
Main Methods:
- Gene transfer into hematopoietic stem cells to modulate chemotherapy sensitivity.
- Modification of donor T cells for targeted drug activation in graft-versus-leukemia responses.
- Genetic engineering of neoplastic cells to increase drug sensitivity or immunogenicity.
- Utilizing genes encoding immune stimulatory molecules like CD154.
Main Results:
- Gene therapy can reduce myeloid cell sensitivity to chemotherapy.
- Modified T cells enable safer use of prodrugs in allogeneic transplantation.
- Enhancing neoplastic cell sensitivity to drugs and immunogenicity is achievable.
- CD154 gene transfer reversed leukemia cell stealth phenotype, with promising Phase I trial results.
Conclusions:
- Gene therapy presents a promising frontier for treating hematologic malignancies.
- The ability to modify various cell types offers versatile therapeutic avenues.
- Advancements in gene transfer technologies are paving the way for effective clinical applications.